期刊文献+

荧光原位杂交技术检测一例多发性骨髓瘤五类分子细胞遗传学异常

Fluorescence in situ hybridization identifies five cytogenetics aberrations in multiple myeloma
下载PDF
导出
摘要 目的探讨荧光原位杂交(fluorescence in situ hybridization,FISH)技术在检测多发性骨髓瘤(multiple myeloma,MM)1q21缺失、RB1缺失、D13S319缺失、p53缺失和IgH相关易位五类分子细胞遗传学异常中的应用价值。方法应用不同荧光素标记的1q21/RB1、D13S319/p53、14q32(IgH基因)三组探针检测分析10例正常骨髓涂片标本和1例MM患者骨髓涂片标本。结果 FISH技术以10例正常骨髓标本建立参考范围,检测出该例MM患者骨髓核型中存在RB1纯合性缺失。结论 FISH技术可以检测出MM患者的分子细胞遗传学异常。 Objective To explore the value of the technique of fluorescence in situ hybridization(FISH) in the identification of 1q21 deletion、RB1 deletion、D13S319 deletion、p53deletion and IgH translocations five cytogenetics aberrations in multiple myeloma(MM). Method Ten normal and one MM bone marrow(BW)smears were detected and analyzed by FISH which had different fluorescence labeled three pairs of probes( 1q21/RB1、D13S319/p53、14q32(gene IgH)). Result With the reference range of ten normal BW specimen, FISH could identify the loss of puriosity of RB1 in the MM patient. Conclusion FISH could identify aberrations in MM patient.
作者 孙毅 刘静芸
出处 《临床检验杂志(电子版)》 2013年第4期480-484,共5页 Clinical Laboratory Journal(Electronic Edition)
关键词 荧光原位杂交 多发性骨髓瘤 分子细胞遗传学 fluorescence in situ hybridization multiple myeloma cytogenetics
  • 相关文献

参考文献4

  • 1李利红,陈文明.多发性骨髓瘤的分子学研究进展[J].白血病.淋巴瘤,2005,14(1):56-58. 被引量:4
  • 2HongChang,StephenSloan,DanLi,A.Keith Stewart.Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions[J].British Journal of Haematology.2004(3)
  • 3Nicole VéroniqueSmadja,DominiqueLeroux,JeanSoulier,SylvieDumont,CatherineArnould,SylvieTaviaux,Jean LouisTaillemite,ChristianBastard.Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases[J].Genes Chromosom Cancer.2003(3)
  • 4ThérèseNilsson,MattiasH?glund,StigLenhoff,LarsRylander,IngemarTuresson,JanWestin,FelixMitelman,BertilJohansson.A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age‐ and sex‐related differences[J].British Journal of Haematology.2003(6)

二级参考文献21

  • 1Carli P M, Coebergh J W, Verdecchia A, et al. Variation in survival of adult patients with haematological malignancies in Europe since1978[J]. Eur J Cancer, 1998,34:2253-2263.
  • 2Heinrich P C, Behrmann I, Haan S, et al.Principles of interleukin (IL)-6-type cytokine signalling and its regulation [J]. Biochem J,2003, 8(15):1-20.
  • 3Sezer O, Heider U, Zavrski I, at al. RANK ligand and osteoprotegerin in myeloma bone disease[J]. Blood, 2003,101 (6): 2094 - 2098.
  • 4Firkin F, Schneider H, Grill V. Parathyroid hormone- related protein in hypercalcemia associated with hematological malignancy[J].Leuk Lymph, 1998, 29:499-506.
  • 5Hjertner Q, Torgersen M L, Seidel C, et al.Hepatocyte growth factor (HGF) induces interleukin - 11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease[J]. Blood, 1999, 94(11): 3883-3888.
  • 6Nakatsuka K. Development of bisphosphonates[J]. Nippon Rinsho, 2003, 61 (2): 219-225.
  • 7Aref S, Goda T, El-Sherbinyb M. Syndecan1 in multiple myeloma: relationship to conventional prognostic factors [J]. Hematology,2003, 8(4): 221-228.
  • 8Yang Y, Yaccoby S, Liu W. Soluble syndecan- 1 promotes growth of myeloma tumors in vivo[J]. Blood, 2002, 100(2): 610-617.
  • 9Chatterjee M, Honemann D, Lentzsch S, et al.In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6 / gp130 / STAT3 pathway[J]. Blood, 2002,100(8): 3311-3318.
  • 10Kelly T, Borset M, Abe E, et al. Matrix metalloproteinases in multiple myeloma [J]. Leuk Lymphoma, 2000, 37(3-4): 273-281.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部